Observing Fruquintinib Treatment in Adults With Metastatic Colorectal Cancer in Germany

What this Trial Is About

This research aims to evaluate how well Fruquintinib works in treating adults with metastatic colorectal cancer mCRC who have already received standard treatments. The study is observational and collects real-world data from patients in Germany, focusing on how patients respond to Fruquintinib, survival, safety, medical care use, and quality of life. It includes a translational research project to link clinical data with tumor and blood biomarkers to understand which patients benefit most. Participants receive Fruquintinib as prescribed by their doctors according to routine clinical practice. The study plans to recruit about 150 patients across 50 centers, including offices, outpatient oncology centers, and hospitals. Archival tumor tissue and blood samples are collected to study biomarkers, and circulating tumor DNA is monitored over time to assess treatment response. During the study, patients disease control rates, treatment responses, survival times, adverse events, and quality of life will be measured. Data on treatment duration, modifications, hospital visits, and use of medical care will also be recorded. The study follows participants for up to 33 months, monitoring clinical outcomes and biomarker changes to better understand Fruquintinibs effects in real-world settings.

Fruquintinib in Patients With Metastatic Colorectal Cancer